Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BXRX source : Www.biospace.com save search
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
Published: 2023-04-25 (Crawled : 13:20) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 63.83%
H: 12.66%
C: -32.14%
bx1000 positive trial results phase 2
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
Published: 2023-03-27 (Crawled : 13:20) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 16.13%
H: 16.11%
C: 7.78%
bx1000 positive trial phase 2
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
Published: 2023-02-23 (Crawled : 15:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: -0.4%
H: 2.38%
C: -11.51%
financial update results
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
Published: 2023-01-24 (Crawled : 14:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 94.29%
H: 12.58%
C: -31.86%
bx1000 trial positive
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
Published: 2022-12-08 (Crawled : 14:20) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 4.15%
H: 22.51%
C: 15.95%
bx1000 trial
Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference
Published: 2022-09-08 (Crawled : 01:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -6.24%
conference
Baudax Bio Announces Pricing of $6.2 Million Public Offering - Aug 30, 2022
Published: 2022-08-30 (Crawled : 06:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: -40.03%
H: 7.98%
C: -5.07%
offering
Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain
Published: 2022-08-22 (Crawled : 14:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 0.0%
H: 1.81%
C: -6.25%
anjeso treatment patent application
Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
CPB | $43.71 0.92% 0.0% 2.3M
|
Consumer Non-Durables
|
| O: -0.62%
H: 1.58%
C: 0.86%
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 2.86%
H: 1.44%
C: -1.17%
growth
Alkermes plc Reports First Quarter 2022 Financial Results
Published: 2022-04-27 (Crawled : 14:20) - biospace.com/
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: 0.3%
H: 1.11%
C: -0.33%
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 0.67%
H: 4.05%
C: 3.38%
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
|
| O: 13.01%
H: 2.29%
C: -0.95%
results
Baudax Bio Regains Compliance with NASDAQ Listing Requirements
Published: 2022-03-07 (Crawled : 14:30) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 1.74%
H: 0.26%
C: -9.71%
nasdaq
Baudax Bio Announces Pricing of $10.0 Million Public Offering - Feb 25, 2022
Published: 2022-02-25 (Crawled : 09:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: -46.37%
H: 0.0%
C: 0.0%
offering ces
Baudax Bio Announces $4.2 Million Registered Direct Offering
Published: 2021-12-28 (Crawled : 15:30) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: -23.27%
H: 6.43%
C: 1.76%
offering
Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000
Published: 2021-11-11 (Crawled : 14:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 3.48%
H: 0.22%
C: -5.73%
Baudax Bio to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 0.5%
H: 3.98%
C: -0.25%
financial results results conference
Baudax Bio to Present at the NobleCon Pain Management Investor Forum
Published: 2021-10-05 (Crawled : 12:15) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 0.0%
H: 1.8%
C: -1.82%
Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: -0.73%
H: 1.2%
C: -0.93%
life science
Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: -0.2%
H: 0.9%
C: -0.16%
conference
Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights
Published: 2021-08-05 (Crawled : 12:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: -1.93%
H: 1.39%
C: -5.08%
financial results results
Baudax Bio Announces Date of Reconvened Special MeetingSpecial Meeting to be reconvened on August 11, 2021 solely with respect to Proposal 1
Published: 2021-07-30 (Crawled : 00:20) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.